Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer

Oncotarget

Volumn 7, Issue 49, 2016, Pages 81778-81790

  Kwak, Yoonjin ^a,b   Koh, Jiwon ^b   Kim, Duck Woo ^a   Kang, Sung Bum ^a   Kim, Woo Ho ^b   Lee, Hye Seung ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; Immunoscore; Tumor associated macrophage; Tumor infiltrating lymphocytes

Indexed keywords

CD163 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; K RAS PROTEIN; TRANSCRIPTION FACTOR FOXP3; B RAF KINASE; BRAF PROTEIN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; KRAS PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIMARY TUMOR; TUMOR ASSOCIATED LEUKOCYTE; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MACROPHAGE; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; TUMOR INVASION;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; CD3 COMPLEX; CD8-POSITIVE T-LYMPHOCYTES; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS;

EID: 85001020566     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13207     Document Type: Article

References (40)

1. Muller-Hubenthal B, Azemar M, Lorenzen D, Huber M, Freudenberg MA, Galanos C, Unger C, Hildenbrand B. Tumour Biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res. 2009; 29: 4795-805.
2. Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol. 2005; 17: 187-94. doi: 10.1016/j.coi.2005.01.011.
3. Di Caro G, Marchesi F, Laghi L, Grizzi F. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med. 2013; 17: 1088-95. doi: 10.1111/jcmm.12117.
4. Giraldo NA, Becht E, Remark R, Damotte D, Sautes-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol. 2014; 27: 8-15. doi: 10.1016/j.coi.2014.01.001.
5. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77: 1303-10. doi: 10.1002/(sici)1097-0142(19960401)77:7<1303::aidcncr12>3.0.co;2-5.
6. Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, Island E, Satoskar R, Banovac F, et al. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res. 2016; 4: 419-30. doi: 10.1158/2326-6066.cir-15-0110.
7. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015; 26: 259-71. doi: 10.1093/annonc/mdu450.
8. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016. doi: 10.1038/nrc.2016.36.
9. Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer. 2010; 116: 5188-99. doi: 10.1002/cncr.25293.
10. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, et al. Density of tumorinfiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016; 5: e1057388. doi: 10.1080/2162402x.2015.1057388.
11. Bremnes RM, Busund LT, Kilvaer TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC, Donnem T. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11: 789-800. doi: 10.1016/j.jtho.2016.01.015.
12. Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication (in press). Breast Cancer. 2016. doi: 10.1007/s12282-016-0698-z.
13. Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016; 38: 1074-84. doi: 10.1002/hed.24406.
14. Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ, Xie CM, Hu QG. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016; 7: 13765-81. doi: 10.18632/oncotarget.7282.
15. Zikich D, Schachter J, Besser MJ. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma. Immunotherapy. 2016; 8: 35-43. doi: 10.2217/imt.15.99.
16. Mihm MC, Jr., Mule JJ. Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response. Cancer Immunol Res. 2015; 3: 827-35. doi: 10.1158/2326-6066.cir-15-0143.
17. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12: 298-306. doi: 10.1038/nrc3245.
18. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014; 232: 199-209. doi: 10.1002/path.4287.
19. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10: 205. doi: 10.1186/1479-5876-10-205.
20. Lea D, Haland S, Hagland HR, Soreide K. Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era. Scand J Gastroenterol. 2014; 49: 1153-63. doi: 10.3109/00365521.2014.950692.
21. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pages F, Tartour E, Sautes-Fridman C. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol. 2011; 344: 1-24. doi: 10.1007/82_2010_46.
22. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009; 27: 5944-51 doi: 10.1200/JCO.2008.19.6147.
23. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23: 549-55. doi:
24. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015; 36: 229-39. doi: 10.1016/j. it.2015.02.004.
25. Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2016; 35: 671-82. doi: 10.1038/onc.2015.132.
26. Bingle L, Brown NJ, Lewis CE. The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196: 254-65. doi: 10.1002/path.1027.
27. Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H, Zatloukal K. Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch. 2004; 445: 160-7. doi: 10.1007/s00428-004-1051-z.
28. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005; 11: 1210-4.
29. Kim KJ, Wen XY, Yang HK, Kim WH, Kang GH. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. PLoS One. 2015; 10: e0144192. doi: 10.1371/journal.pone.0144192.
30. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012; 7: e47045. doi: 10.1371/journal. pone.0047045.
31. Lavotshkin S, Jalas JR, Torisu-Itakura H, Ozao-Choy J, Lee JH, Sim MS, Stojadinovic A, Wainberg Z, Bifulco CB, Fox BA, Bilchik AJ. Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging. J Gastrointest Surg. 2015; 19: 999-1006. doi: 10.1007/s11605-015-2759-6.
32. Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2014; 20: 331-43. doi: 10.1158/1078-0432.ccr-13-1736.
33. Turksma AW, Coupe VM, Shamier MC, Lam KL, de Weger VA, Belien JA, van den Eertwegh AJ, Meijer GA, Meijer CJ, Hooijberg E. Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy. Clin Cancer Res. 2016; 22: 346-56. doi: 10.1158/1078-0432. ccr-13-2462.
34. Mei Z, Liu Y, Liu C, Cui L. Response to comment on 'Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis'. Br J Cancer. 2014; 111: 2372-3. doi: 10.1038/bjc.2014.285.
35. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-4. doi: 10.1126/science.1129139.
36. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102: 18538-43. doi: 10.1073/pnas.0509182102.
37. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011; 29: 610-8. doi: 10.1200/jco.2010.30.5425.
38. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014; 20: 1891-9. doi: 10.1158/1078-0432.ccr-13-2830.
39. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity. 2016; 44: 698-711 doi: 10.1016/j.immuni.2016.02.025.
40. Lee HS, Kim WH. Tissue array methods for highthroughput clinicopathologic research. Cancer Res Treat. 2006; 38: 1-6. doi: 10.4143/crt.2006.38.1.1.